The performance status gap in immunotherapy for frail patients with advanced non-small cell lung cancer.

ABSTRACT:

Purpose

In advanced non-small cell lung cancer (NSCLC), immune checkpoint inhibitor (ICI) monotherapy is often preferred over intensive ICI treatment for frail patients and those with poor performance status (PS). Among those with poor PS, the additional effect of frailty on treatment selection and mortality is unknown.

Methods

Patients in the veterans affairs national precision oncology program from 1/2019-12/2021 who received first-line ICI for advanced NSCLC were followed until death or study end 6/2022. Association of an electronic frailty index with treatment selection was examined using logistic regression stratified by PS. We also examined overall survival (OS) on intensive treatment using Cox regression stratified by PS. Intensive treatment was defined as concurrent

SUBMITTER: Wu JT 

PROVIDER: S-EPMC11219626 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature